Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | LN-145 |
Trade Name | |
Synonyms | LN145 |
Drug Descriptions |
LN145 comprises autologous tumor infiltrating lymphocytes that are isolated and expanded with IL-2, followed by infusion, potentially resulting in tumor cell death (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C135634 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Aldesleukin + Cyclophosphamide + Fludarabine + LN-145 + Pembrolizumab | Aldesleukin Cyclophosphamide Fludarabine LN-145 Pembrolizumab | 0 | 1 |
Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna | Cyclophosphamide Fludarabine Interleukin-12 LN-145 Mesna | 0 | 1 |
Durvalumab + LN-145 | Durvalumab LN-145 | 0 | 1 |
LN-145 | LN-145 | 0 | 7 |
LN-145 + Pembrolizumab | LN-145 Pembrolizumab | 0 | 1 |